Clinical Trials Logo

NRF2 Mutation clinical trials

View clinical trials related to NRF2 Mutation.

Filter by:
  • None
  • Page 1

NCT ID: NCT04698681 Terminated - Clinical trials for Non-Small Cell Lung Cancer

NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial

Start date: January 19, 2021
Phase:
Study type: Observational

This is a multicenter screening protocol designed to identify patients with NSCLC who have tumor mutations in the KEAP1 or NRF2/NFE2L2 genes in order to determine potential eligibility for a biomarker selected clinical trial (CX-839-014, otherwise known as the KEAPSAKE trial). Circulating tumor DNA (ctDNA) present in blood samples collected from eligible patients will be analyzed by next generation sequencing (NGS) for selected biomarkers. A commercial liquid biopsy NGS test will be provided to study participants free of charge.